Abiopharma

The Chemours Company Provides Update on Second Quarter 2025 Outlook

New Form 6-K - Sanofi Filed: 2025-06-18 AccNo: 0001193125-25-142340 Size: 29 KB

New Form 6-K - Haleon plc Filed: 2025-06-18 AccNo: 0001654954-25-007145 Size: 34 KB

New Form 6-K - GSK plc Filed: 2025-06-18 AccNo: 0001654954-25-007141 Size: 1 MB

New Form EFFECT - Processa Pharmaceuticals, Inc. Filed: 2025-06-17 AccNo: 9999999995-25-001951 Size: 1 KB

New Form EFFECT - Genprex, Inc. Filed: 2025-06-17 AccNo: 9999999995-25-001950 Size: 1 KB

Disclosure of Interest/ Changes in Interest of Substantial Shareholder(s)/ Unitholder(s): DISCLOSURE OF CHANGES IN INTEREST OF SUBSTANTIAL SHAREHOLDER-Q & M DENTAL GROUP (SINGAPORE) LIMITED

Disclosure of Interest/ Changes in Interest of Director/ Chief Executive Officer: DISCLOSURE OF CHANGES IN INTEREST OF DIRECTOR - DR NG CHIN SIAU

General Announcement: CHANGES IN SUBSTANTIAL SHAREHOLDERS INTEREST PURSUANT TO SECTION 138 OF THE COMPANIES ACT 2016

Mandatory Cash Dividend/ Distribution:

FDA approve PLERIXAFOR

FDA approve TRAZODONE HYDROCHLORIDE

FDA approve FINASTERIDE

FDA approve MONTELUKAST SODIUM

FDA approve ITRACONAZOLE